Emergence of oseltamivir-resistant H7N9 influenza viruses in immunosuppressed cynomolgus macaques

Journal of Infectious Diseases

Volumn 216, Issue 5, 2017, Pages 582-593

  Kiso, Maki ^a   Iwatsuki Horimoto, Kiyoko ^a   Yamayoshi, Seiya ^a   Uraki, Ryuta ^a   Ito, Mutsumi ^a   Nakajima, Noriko ^b   Yamada, Shinya ^a   Imai, Masaki ^a   Kawakami, Eiryo ^c   Tomita, Yuriko ^a   Fukuyama, Satoshi ^a,d   Itoh, Yasushi ^e   Ogasawara, Kazumasa ^e   Lopes, Tiago J S ^a,f   Watanabe, Tokiko ^a,d   Moncla, Louise H ^f,g   Hasegawa, Hideki ^b   Friedrich, Thomas C ^f,g   Neumann, Gabriele ^f   Kawaoka, Yoshihiro ^a,d,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Institute of Physical and Chemical Research   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Immunosuppression; Influenza virus; Nonhuman primates; Oseltamivir resistance

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT; INFLUENZA VIRUS HEMAGGLUTININ; SIALIDASE;

ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; IMMUNOCOMPETENCE; INFLUENZA A (H7N9); LOW DRUG DOSE; MACACA FASCICULARIS; MALE; MORTALITY; MUSTELA PUTORIUS FURO; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOCOMPROMISED PATIENT; INFLUENZA A VIRUS (H7N9); METABOLISM; MULTIDRUG RESISTANCE; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; VETERINARY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H7N9 SUBTYPE; MACACA FASCICULARIS; MALE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; VIRUS REPLICATION;

EID: 85030615823     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix296     Document Type: Article

References (48)

1. Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses 2015; 7:4929-44.
2. Leang SK, Deng YM, Shaw R, et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res 2013; 97:206-10.
3. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-402.
4. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-17.
5. Duan S, Boltz DA, Seiler P, et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010; 6:e1001022.
6. Meijer A, Lackenby A, Hungnes O, et al; European Influenza Surveillance Scheme. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-60.
7. Renaud C, Boudreault AA, Kuypers J, et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011; 17:653-60; quiz 765.
8. Eshaghi A, Patel SN, Sarabia A, et al. Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg Infect Dis 2011; 17:1472-4.
9. Ruiz-Carrascoso G, Casas I, Pozo F, González-Vincent M, Pérez-Breña P. Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant. Antivir Ther 2010; 15:1059-63.
10. Baranovich T, Burnham AJ, Marathe BM, et al. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis 2014; 209:1343-53.
11. Cao RY, Xiao JH, Cao B, Li S, Kumaki Y, Zhong W. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antivir Chem Chemother 2014; 23:237-40.
12. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-9.
13. Liu X, Li T, Zheng Y, Wong K W, Lu S, Lu H. Poor responses to oseltamivir treatment in a patient with influenza A (H7N9) virus infection. Emerg Microbes Infect 2013; 2:e27.
14. Watanabe T, Kiso M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013; 501:551-5.
15. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4:e1000225.
16. Schröder C, Pfeiffer S, Wu G, et al. Simian parvovirus infection in cynomolgus monkey heart transplant recipients causes death related to severe anemia. Transplantation 2006; 81:1165-70.
17. Pham VL, Nakayama M, Itoh Y, et al. Pathogenicity of pandemic H1N1 influenza A virus in immunocompromised cynomolgus macaques. PLoS One 2013; 8:e75910.
18. Itoh Y, Shichinohe S, Nakayama M, et al. Emergence of H7N9 influenza A virus resistant to neuraminidase inhibitors in nonhuman primates. Antimicrob Agents Chemother 2015; 59:4962-73.
19. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460:1021-5.
20. Muramoto Y, Shoemaker JE, Le MQ, et al. Disease severity is associated with differential gene expression at the early and late phases of infection in nonhuman primates infected with different H5N1 highly pathogenic avian influenza viruses. J Virol 2014; 88:8981-97.
21. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 2001; 75:6687-91.
22. Moncla LH, Zhong G, Nelson CW, et al. Selective bottlenecks shape evolutionary pathways taken during mammalian adaptation of a 1918-like avian influenza virus. Cell Host Microbe 2016; 19:169-80.
23. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 2002; 53:47-61.
24. Davis EA, Pruitt SK, Greene PS, et al. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation 1996; 62:1018-23.
25. Rijkelijkhuizen JK, Bouwman E, van der Burg MP, et al. Successful suppression of the early rejection of pig islets in monkeys. Cell Transplant 2000; 9:909-12.
26. Bashuda H, Kimikawa M, Seino K, et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest 2005; 115:1896-902.
27. Watanabe T, Imai M, Watanabe S, et al. Characterization in vitro and in vivo of pandemic (H1N1) 2009 influenza viruses isolated from patients. J Virol 2012; 86:9361-8.
28. Watanabe T, Shinya K, Watanabe S, et al. Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaques. J Virol 2011; 85:13195-203.
29. Elbahlawan L, Gaur AH, Furman W, et al. Severe H1N1-associated acute respiratory failure in immunocompromised children. Pediatr Blood Cancer 2011; 57:625-8.
30. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98:174-85.
31. Wang D, Sleeman K, Huang W, et al. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral Res 2013; 97:240-4.
32. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:1257-62.
33. Tamura D, Nguyen HT, Sleeman K, et al. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother 2013; 57:6141-6.
34. Fujisaki S, Takashita E, Yokoyama M, et al. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochem Biophys Res Commun 2012; 429:51-6.
35. Nguyen HT, Trujillo AA, Sheu TG, et al. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antiviral Res 2012; 93:381-6.
36. Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4:2854.
37. Meijer A, Rebelo-de-Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res 2014; 110:31-41.
38. Matrosovich M, Tuzikov A, Bovin N, et al. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol 2000; 74:8502-12.
39. Asaoka N, Tanaka Y, Sakai T, Fujii Y, Ohuchi R, Ohuchi M. Low growth ability of recent influenza clinical isolates in MDCK cells is due to their low receptor binding affinities. Microbes Infect 2006; 8:511-9.
40. Watanabe Y, Arai Y, Daidoji T, et al. Characterization of H5N1 influenza virus variants with hemagglutinin mutations isolated from patients. MBio 2015; 6:e00081-15.
41. Tamura D, DeBiasi RL, Okomo-Adhiambo M, et al. Emergence of multidrug-resistant influenza A(H1N1) pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J Infect Dis 2015; 212:1209-13.
42. van der Vries E, Stittelaar KJ, van Amerongen G, et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog 2013; 9:e1003343.
43. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 2006; 193:765-72.
44. Sidwell RW, Bailey K W, Morrey JD, Wong MH, Baldwin TJ, Smee DF. Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812). Antiviral Res 2003; 60:17-25.
45. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2013; 18:651-61.
46. Qiu S, Shen Y, Pan H, Wang J, Zhang Q. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infect Dis (Lond) 2015; 47:808-19.
47. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2547.
48. Kashiwagi S, Yoshida S, Yamaguchi H, et al. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. J Infect Chemother 2013; 19:223-32.